ECSP11010959A - Inhibidores de la integrasa del vih - Google Patents

Inhibidores de la integrasa del vih

Info

Publication number
ECSP11010959A
ECSP11010959A EC2011010959A ECSP11010959A ECSP11010959A EC SP11010959 A ECSP11010959 A EC SP11010959A EC 2011010959 A EC2011010959 A EC 2011010959A EC SP11010959 A ECSP11010959 A EC SP11010959A EC SP11010959 A ECSP11010959 A EC SP11010959A
Authority
EC
Ecuador
Prior art keywords
compounds
inhibitors
hiv
prophylaxis
aids
Prior art date
Application number
EC2011010959A
Other languages
English (en)
Inventor
Dai-Shi Su
John S Wai
David C Dubost
Richard C Isaacs
Mark Embrey
Thorsten E Fisher
Wayne J Thompson
Peter D Williams
Shankar Venkatraman
Richard G Ball
Eric J Choi
Tao Pei
Sarah L Trice
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of ECSP11010959A publication Critical patent/ECSP11010959A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compuestos de Fórmula I son inhibidores de la integrasa del VIH e inhibidores de replicación del VIH:(I).donde X1, X2, Y, R1A, R1B, R2 y R3 se definen en este documento. Los compuestos son útiles para la profilaxis o tratamiento de una infección por el VIH y la profilaxis, tratamiento o retardo en la aparición o progresión del SIDA. Los compuestos se emplean frente a una infección del VIH y SIDA como compuestos en sí mismos (o como hidratos o solvatos de los mismos) o en forma de sales farmacéuticamente aceptables. Los compuestos y sus sales se pueden emplear como ingredientes en composiciones farmacéuticas, opcionalmente en combinación con otros antivirales, inmunomoduladores, antibióticos o vacunas.
EC2011010959A 2008-10-06 2011-04-06 Inhibidores de la integrasa del vih ECSP11010959A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19527108P 2008-10-06 2008-10-06

Publications (1)

Publication Number Publication Date
ECSP11010959A true ECSP11010959A (es) 2011-05-31

Family

ID=41682332

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011010959A ECSP11010959A (es) 2008-10-06 2011-04-06 Inhibidores de la integrasa del vih

Country Status (22)

Country Link
US (2) US8513234B2 (es)
EP (1) EP2349276B1 (es)
JP (2) JP4880097B1 (es)
KR (1) KR20110066224A (es)
CN (1) CN102239172A (es)
AR (1) AR073769A1 (es)
AU (1) AU2009302663B2 (es)
BR (1) BRPI0920605A8 (es)
CA (1) CA2738814C (es)
CO (1) CO6382127A2 (es)
CR (1) CR20110184A (es)
DO (1) DOP2011000093A (es)
EA (1) EA201170537A1 (es)
EC (1) ECSP11010959A (es)
IL (1) IL212019A0 (es)
MA (1) MA32764B1 (es)
MX (1) MX2011003637A (es)
NI (1) NI201100069A (es)
PE (1) PE20110344A1 (es)
TW (1) TW201020251A (es)
WO (2) WO2010042392A2 (es)
ZA (1) ZA201102620B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8283366B2 (en) 2010-01-22 2012-10-09 Ambrilia Biopharma, Inc. Derivatives of pyridoxine for inhibiting HIV integrase
WO2014008636A1 (en) * 2012-07-11 2014-01-16 Merck Sharp & Dohme Corp. Macrocyclic compounds as hiv integrase inhibitors
CN102936188B (zh) * 2012-11-19 2015-07-15 湖北吉和昌化工科技有限公司 一种丙炔醇缩水甘油醚的合成方法
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
CN107722106A (zh) * 2016-08-11 2018-02-23 重庆大学 Hiv抑制剂
KR20240151256A (ko) 2019-03-22 2024-10-17 길리애드 사이언시즈, 인코포레이티드 가교된 트리시클릭 카르바모일피리돈 화합물 및 그의 제약 용도
EP4110783A1 (en) 2020-02-24 2023-01-04 Gilead Sciences, Inc. Tetracyclic compounds for treating hiv infection
CN111454214B (zh) * 2020-05-27 2023-04-07 龙曦宁(上海)医药科技有限公司 一种2-甲氧基1-嘧啶乙胺盐酸盐的合成方法
CN116390924B (zh) 2020-09-30 2025-11-07 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
CR20260070A (es) 2021-01-19 2026-04-24 Gilead Sciences Inc COMPUESTOS DE PIRIDOTRIAZINA SUSTITUIDOS Y USOS DE ESTOS (Divisional 2023-0315)
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE530520T1 (de) * 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
CA2463975A1 (en) * 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
DE122009000048I1 (de) * 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
EP1467970B1 (en) * 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
WO2004058756A1 (en) * 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
WO2004062613A2 (en) * 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) * 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) * 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
ATE419249T1 (de) * 2004-04-06 2009-01-15 Novartis Vaccines & Diagnostic Inhibitoren von mitotischem kinesin
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) * 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7192948B2 (en) * 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) * 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) * 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) * 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2006060225A2 (en) 2004-11-23 2006-06-08 Merck & Co., Inc. Process for asymmetric synthesis of hexahydropyrimido[1,2-a] azepine-2-carboxamides and related compounds
WO2006103399A1 (en) 2005-03-31 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
WO2007059125A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors
WO2007058646A1 (en) 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors: cyclic pyrimidinone compounds
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) * 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (en) 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
WO2007143446A1 (en) * 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors

Also Published As

Publication number Publication date
AU2009302663B2 (en) 2012-11-08
MX2011003637A (es) 2011-04-27
CR20110184A (es) 2011-06-08
EP2349276B1 (en) 2019-11-27
IL212019A0 (en) 2011-06-30
JP2012036207A (ja) 2012-02-23
EP2349276A2 (en) 2011-08-03
WO2010042392A3 (en) 2010-06-03
JP2012504648A (ja) 2012-02-23
DOP2011000093A (es) 2011-07-15
CA2738814C (en) 2014-01-28
PE20110344A1 (es) 2011-06-22
US8513234B2 (en) 2013-08-20
AR073769A1 (es) 2010-12-01
CN102239172A (zh) 2011-11-09
BRPI0920605A2 (pt) 2015-12-22
US20100087419A1 (en) 2010-04-08
WO2010042392A2 (en) 2010-04-15
ZA201102620B (en) 2011-12-28
AU2009302663A1 (en) 2010-04-15
NI201100069A (es) 2012-08-08
CO6382127A2 (es) 2012-02-15
JP4880097B1 (ja) 2012-02-22
KR20110066224A (ko) 2011-06-16
TW201020251A (en) 2010-06-01
EA201170537A1 (ru) 2011-12-30
WO2010042391A2 (en) 2010-04-15
CA2738814A1 (en) 2010-04-15
MA32764B1 (fr) 2011-11-01
BRPI0920605A8 (pt) 2016-04-26
WO2010042391A3 (en) 2010-06-03
JP5600311B2 (ja) 2014-10-01
US20130338141A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
CO6382127A2 (es) Inhibidores de la integrasa del vih
CY1122585T1 (el) Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο ηiv
ECSP12012201A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
ECSP099373A (es) Inhibidores de transcriptasa inversa no nucleosídicos
CO2018001296A2 (es) Compuestos antivirales de fosfodiamida de éster de beta-aminoácido
CR9694A (es) Inhibidores de la transcriptasa reversa de vih
ECSP066826A (es) Inhibidores de integrasa de vih
DOP2006000176A (es) Inhibidores de la transcriptasa reversa de vih
TN2011000151A1 (en) Hiv integrase inhibitors
DOP2005000105A (es) Inhibidores de la integrasa del vih
CY1116437T1 (el) Μη νουκλεοσιδικοι αναστολεις αναστροφης μεταγραφασης
ECSP088126A (es) Inhibidores de la transcriptasa reversa de vih